Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Biotechnology

Healthcare
$42.53 -1.86%

-$0.62 today

Market cap
$800.84M
Beta
1.18
P/E (TTM)
1.7
EPS (TTM)
$19.78
52W Low $18.14High $52.24

Volume 0.24M

Average 0.36M

RIGL Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Rigel Pharmaceuticals, Inc.NASDAQ: RIGL

Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Investing cash flow dips below year-ago levels

Q1 FY2026 investing cash flow of $7.98M (cash outflow) fell 24.4% year over year, behind the +1233.2% change in trailing-twelve-month investing cash flow. Sequentially, it fell 68.6% from the prior quarter.

Context

  • Investing cash flow amounted to 31.4% of revenue in FY2025, up 29.1 pp from a year earlier.
  • Investing cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -24.4% toward the trailing-twelve-month pace of +1233.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$7.98M-68.6% QoQ
Last fiscal yearDec 2025
-$92.37M-2336.4% YoY
LTMMar 2026
-$89.79M+1233.2% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-24.4%——
1 year-2336.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
(92.37M) USD
Year-over-year change
-2336.4%

Investing Cash Flow vs competitors

How RIGL compares with its peers on the latest reported figures

  • RIGL's LTM Mar 2026 investing cash flow of $89.79M is the 3rd largest of the 10 companies compared; the peer median is $3.04K.
  • Its year-over-year change of +1233.2% is the highest of 9, against a peer median of -91.3%.
  • Investing cash flow amounts to 30.0% of revenue for RIGL, versus a peer median of 51.7%.
RIGL Competitors Peer median
Investing Cash Flow for RIGL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$175.6M +256.1%-10.3%—
EXELExelixis, Inc.LTM Jul 2026$93.01M +840.9%—3.8%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$89.79M +1233.2%—30.0%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$50.1M -157.3%——
VSTMVerastem, Inc.LTM Mar 2026$25.64M -188.4%—51.7%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$21.57M -169.0%—61.9%
CRDFCardiff Oncology, Inc.LTM Mar 2026$19.18M +449.3%-67.2%3653.9%
ANLAdlai Nortye Ltd.LTM Jun 2024$4.81M ——74.1%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$1.1M -83.6%+75.8%0.2%
MREOMereo BioPharma Group plcLTM Mar 2026$3.04K -99.0%—0.6%
Peer median (excluding RIGL) $3.04K-91.3%-10.3%51.7%

Competitors are the stored peer set for RIGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(17.91M)(58.57M)(25.09M)17.49M367.02M
Depreciation & Amortization1.16M998K1.24M2.23M2.42M
Deferred Income Tax0000(245.85M)
Stock-Based Compensation9.49M12.39M8.81M12.39M12.71M
Change in Working Capital9.72M(29.05M)9.52M153K(19.51M)
Accounts Receivables501K(24.85M)9.77M(11.07M)(10.15M)
Inventory(4.88M)(2.38M)1.17M764K(5.64M)
Accounts Payables41K3.79M(366K)(3.8M)3.85M
Other Working Capital14.05M(5.61M)(1.06M)14.26M(7.58M)
Other Non-Cash Items3.43M481K(213K)(788K)(41.13M)
Operating Cash Flow5.88M(73.76M)(5.74M)31.47M75.66M
Capital Expenditures(627K)(450K)(15M)(396K)0
Acquisitions (Net)00000
Purchases of Investments(141.46M)(28.89M)(31.21M)(35.27M)(153.49M)
Sales of Investments62.05M101.23M41.65M39.7M61.13M
Other Investing Activities0893K259K98K0
Investing Cash Flow(80.04M)72.78M(4.3M)4.13M(92.37M)
Debt Repayment019.54M19.95M0(7.5M)
Common Stock Issued00008.1M
Common Stock Repurchased000(10M)0
Dividends Paid00000
Other Financing Activities62.68M(12.99M)(1.58M)(1.64M)0
Financing Cash Flow62.68M6.55M18.37M(11.64M)601K
Effect of Forex Changes00000
Net Change in Cash(11.48M)5.57M8.33M23.96M(16.11M)
Free Cash Flow5.25M(74.21M)(20.74M)31.08M75.66M

Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Intrinsic Alpha fair value

Locked

Current Price

$42.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.